Clarke PA - Search Results

1

Native Size-Exclusion Chromatography-Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global Changes.

Samant RS, Batista S, Larance M, Ozer B, Milton CI, Bludau I, Wu E, Biggins L, Andrews S, Hervieu A, Johnston HE, Al-Lazikhani B, Lamond AI, Clarke PA, Workman P. Samant RS, et al. Among authors: clarke pa. Mol Cell Proteomics. 2023 Feb;22(2):100485. doi: 10.1016/j.mcpro.2022.100485. Epub 2022 Dec 20. Mol Cell Proteomics. 2023. PMID: 36549590 Free PMC article.

2

Innovative cancer drug targets: genomics, transcriptomics and clinomics.

Workman P, Clarke PA. Workman P, et al. Among authors: clarke pa. Expert Opin Pharmacother. 2001 Jun;2(6):911-5. doi: 10.1517/14656566.2.6.911. Expert Opin Pharmacother. 2001. PMID: 11585007 No abstract available.

3

Assays for HSP90 and inhibitors.

Aherne W, Maloney A, Prodromou C, Rowlands MG, Hardcastle A, Boxall K, Clarke P, Walton MI, Pearl L, Workman P. Aherne W, et al. Methods Mol Med. 2003;85:149-61. doi: 10.1385/1-59259-380-1:149. Methods Mol Med. 2003. PMID: 12710206 Review. No abstract available.

4

Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective.

Maloney A, Clarke PA, Workman P. Maloney A, et al. Among authors: clarke pa. Curr Cancer Drug Targets. 2003 Oct;3(5):331-41. doi: 10.2174/1568009033481822. Curr Cancer Drug Targets. 2003. PMID: 14529385 Review.

5

Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling.

Clarke PA, George ML, Easdale S, Cunningham D, Swift RI, Hill ME, Tait DM, Workman P. Clarke PA, et al. Cancer Res. 2003 Oct 15;63(20):6855-63. Cancer Res. 2003. PMID: 14583483

6

Gene expression microarray technologies in the development of new therapeutic agents.

Clarke PA, te Poele R, Workman P. Clarke PA, et al. Eur J Cancer. 2004 Nov;40(17):2560-91. doi: 10.1016/j.ejca.2004.07.024. Eur J Cancer. 2004. PMID: 15541959 Review.

7

Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.

Hardcastle A, Boxall K, Richards J, Tomlin P, Sharp S, Clarke P, Workman P, Aherne W. Hardcastle A, et al. Assay Drug Dev Technol. 2005 Jun;3(3):273-85. doi: 10.1089/adt.2005.3.273. Assay Drug Dev Technol. 2005. PMID: 15971989

8

Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, Yang A, Zvelebil M, Cramer R, Stimson L, Aherne W, Banerji U, Judson I, Sharp S, Powers M, deBilly E, Salmons J, Walton M, Burlingame A, Waterfield M, Workman P. Maloney A, et al. Among authors: clarke pa. Cancer Res. 2007 Apr 1;67(7):3239-53. doi: 10.1158/0008-5472.CAN-06-2968. Cancer Res. 2007. PMID: 17409432

9

Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.

Powers MV, Clarke PA, Workman P. Powers MV, et al. Among authors: clarke pa. Cancer Cell. 2008 Sep 9;14(3):250-62. doi: 10.1016/j.ccr.2008.08.002. Cancer Cell. 2008. PMID: 18772114 Free article.

10

Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors.

Smith JR, Clarke PA, de Billy E, Workman P. Smith JR, et al. Among authors: clarke pa. Oncogene. 2009 Jan 15;28(2):157-69. doi: 10.1038/onc.2008.380. Epub 2008 Oct 20. Oncogene. 2009. PMID: 18931700 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

205 results

Search Page

Filters